Pfizer Deferred Revenue decreased by 15.2% to $784.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 48.1%, from $1.51B to $784.00M. Over 5 years (FY 2020 to FY 2025), Deferred Revenue shows a downward trend with a -6.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong sales of subscription-based services or bundled offerings, providing a predictable pipeline for future revenue recognition.
Represents cash payments received from customers in advance of the company fulfilling its performance obligations, speci...
High-growth software and services companies typically maintain larger deferred revenue balances relative to pure hardware manufacturers.
deferred_revenue_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.29B | $3.53B | $3.07B | $300.00M | $200.00M | $200.00M | $2.52B | $13.00B | $9.00B | $9.00B | $2.70B | $2.50B | $2.53B | $2.02B | $1.51B | $1.01B | $1.12B | $924.00M | $784.00M |
| QoQ Change | — | -17.8% | -13.1% | -90.2% | -33.3% | +0.0% | >999% | +415.9% | -30.8% | +0.0% | -70.0% | -7.3% | +1.0% | -20.1% | -25.2% | -33.0% | +11.0% | -17.7% | -15.2% |
| YoY Change | — | — | — | — | -95.3% | -94.3% | -17.8% | >999% | >999% | >999% | +7.1% | -80.8% | -71.9% | -77.6% | -44.0% | -59.6% | -55.6% | -54.3% | -48.1% |